The First Affiliated Hospital of Soochow University
334
113
124
41
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
1.2%
4 terminated/withdrawn out of 334 trials
91.1%
+4.6% vs industry average
15%
49 trials in Phase 3/4
10%
4 of 41 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (334)
TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis
Role: collaborator
Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
Role: lead
GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma
Role: collaborator
Peripheral Blood KIT-D816V Mutation in Adult Systemic Mastocytosis
Role: lead
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
Role: lead
SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS
Role: lead
A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCT
Role: lead
The Enhancement of Diagnostic and Grading Efficacy of Prostate Cancer by New MRI Sequences: A Prospective Observational Study Based on New MRI Sequences in a Single Center
Role: lead
AI Model for Early Gastric Cancer Diagnosis Using Endoscopic Imaging
Role: lead
Clinical Study of PRP in the Treatment of Androgenetic Alopecia
Role: lead
Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia
Role: lead
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
Role: lead
A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients
Role: lead
Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA
Role: lead
Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients
Role: lead
A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia
Role: lead
Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
Role: lead
Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL
Role: lead
Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
Role: lead
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
Role: lead